Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia

Eli Lilly's RNA Therapy Shows Promise in Treating Mixed Dyslipidemia

Eli Lilly's RNA interference therapy solbinsiran reduced apolipoprotein B (apoB) levels by 14.3% compared to placebo in a Phase 2 trial for mixed dyslipidemia1.

The PROLONG-ANG3 study enrolled 205 patients with mixed dyslipidemia who were taking stable doses of statins9.

Solbinsiran targets the ANGPTL3 gene, a key regulator of triglyceride and lipoprotein metabolism9.

In addition to apoB reduction, solbinsiran lowered levels of ANGPTL3, triglycerides, very-LDL-C, non-HDL-C, and LDL-C9.

The 400 mg dose of solbinsiran showed the most significant results, with reductions in non-HDL cholesterol (26%), LDL cholesterol (17%), and triglycerides and very low-density lipoprotein cholesterol (over 50%)1.

Solbinsiran was generally well-tolerated, with most adverse events being mild or moderate9.

The study results were presented at the American College of Cardiology meeting and published in The Lancet1.

This Phase 2 success positions Eli Lilly as a competitor in the RNA-based lipid-lowering therapy market, alongside companies like AstraZeneca and Merck6.

Sources:

1. https://www.thepharmaletter.com/pharmaceutical/lillys-solbinsiran-shows-promise-in-mid-stage-study

6. https://endpts.com/lilly-claims-phase-2-win-for-sirna-approach-to-mixed-dyslipidemia/

9. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2025/03/28/03/10/prolong-ang3